Nature

Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-Diethylaminoethyl-Dextran Methyl Methacrylate Copolymer Non-Viral Vector–p53

Lung cancer still remains to be challenged by novel treatment modalities. Novel locally targeted routes of administration are a methodology to enhance treatment and reduce side effects. Intratumoral ...
ascopubs.org

Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

PURPOSE: To determine the safety, humoral immune response replication, and activity of multiple intratumoral injections of ONYX-015 (replication selective adenovirus) in patients with recurrent ...
ascopubs.org

Phase I trial of intratumoral administration of reovirus type 3 with radiation in patients with advanced malignancies

Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR-1 with gefitinib sensitivity in patients with non-small cell lung cancer: ...
Business Wire

Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, an emerging clinical-stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced results from a preclinical ...

Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer

LUND, SE / ACCESS Newswire / July 2, 2026 / Alligator Bioscience (STO:ATORX) First patient dosed in an investigator-initiated ...

Alligator Bioscience: Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer

LUND, SE / ACCESS Newswire / July 2, 2026 / Alligator Bioscience (STO:ATORX)First patient dosed in an investigator-initiated trial evaluating intratumoral mitazalimab, with or without intratumoral niv ...